IMA203 phase 1b update to cement leadership position in PRAME
Immatics is expected to report an update in Q4 2023 from its ongoing phase 1b dose expansion trial with the autologous TCR T PRAME therapy IMA203. With this note, we recap the data so far and put forward our readout scenarios. Based on the previous interim update in May 2023, in our base case we ex
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.